Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Upsher-Smith To Buy Biotech Proximagen
by Alex Scott
June 18, 2012
| A version of this story appeared in
Volume 90, Issue 25
Upsher-Smith has agreed to acquire Proximagen Group, a U.K. biotech firm focused on developing therapeutics for inflammation and diseases of the central nervous system. Upsher-Smith, a Minnesota-based specialty drug maker, is paying $347 million plus up to $208 million more depending on the success of two Proximagen drugs in development. Upsher-Smith has been a minor shareholder of Proximagen, as well as a commercial partner, since July 2008. Proximagen, which has 15 drug research programs, started up in 2003 as a spin-off from King’s College London.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X